Arrowhead Pharmaceuticals/ARWR

$24.06

-2.59%
-
1D1W1MYTD1YMAX

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Ticker

ARWR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Anzalone

Employees

525

Headquarters

Pasadena, United States

ARWR Metrics

BasicAdvanced
$3.06B
Market cap
-
P/E ratio
-$2.77
EPS
0.75
Beta
-
Dividend rate
$3.06B
0.74659
$42.48
$20.67
1.26M
3.733
-55.19%
-39.91%
-110.45%
-46.61%
16.839
16.553
20.324
-34.71%
-88.89%
39.86%

What the Analysts think about ARWR

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 13 analysts.
130.17% upside
High $90.00
Low $28.00
$24.06
Current price
$55.38
Average price target

ARWR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,794.28% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.5M
-78.13%
Net income
$-132.8M
21.17%
Profit margin
-3,794.28%
453.91%

ARWR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 51.22%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.45
-$0.96
-$1.02
-$1.24
-
Expected
-$0.64
-$0.65
-$0.60
-$0.82
-$0.16
Surprise
-170.21%
47.01%
69.09%
51.22%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals (ARWR) has a market cap of $3.06B as of April 15, 2024.

What is the P/E ratio for Arrowhead Pharmaceuticals stock?

The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of April 15, 2024.

Does Arrowhead Pharmaceuticals stock pay dividends?

No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Arrowhead Pharmaceuticals dividend payment date?

Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.

What is the beta indicator for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Arrowhead Pharmaceuticals stock price target?

The target price for Arrowhead Pharmaceuticals (ARWR) stock is $55.38, which is 130.17% above the current price of $24.06. This is an average based on projections from 13 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Arrowhead Pharmaceuticals stock

Buy or sell Arrowhead Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing